Core Viewpoint - Jinhe Biology (002688.SZ) expects a net profit increase of 40%-55% for the first half of 2025, projecting a profit range of 127 million to 141 million yuan compared to the same period last year [1] Group 1: Financial Performance - The expected net profit for the first half of 2025 is between 127 million and 141 million yuan, indicating a growth of 40%-55% year-on-year [1] - The growth is attributed to strong sales in the veterinary chemical drug segment, particularly the main product, Chlortetracycline, which saw increased sales in both domestic and overseas markets [1] Group 2: Operational Highlights - The overseas market sales have continued to grow, contributing positively to overall performance [1] - The completion of the sixth phase project has increased production capacity, ensuring supply meets demand and generating additional profits [1] Group 3: Sector Contributions - The agricultural product processing segment benefited from a decline in corn prices, which also contributed to the overall performance improvement [1]

Performance Forecast - The company expects a net profit of 127.43 million to 141.08 million yuan for the period from January 1, 2025, to June 30, 2025, representing a growth of 40% to 55% compared to the same period last year, where the profit was 91.02 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be between 117.83 million and 131.48 million yuan, an increase of 38.70% to 54.78% from last year's 84.95 million yuan [1] - Basic earnings per share are projected to be between 0.1651 yuan and 0.1828 yuan, compared to 0.1166 yuan in the previous year [1] Reasons for Performance Change - The sales of the veterinary chemical drug segment have continued to improve, with significant growth in both domestic and international markets, particularly in the overseas market [1] - The completion of the company's sixth-phase project has increased production capacity, ensuring supply for both domestic and international markets, which has contributed to higher profits [1] - The agricultural product processing segment has benefited from a decline in the price of corn, positively impacting overall performance [1]

证券代码：002688 证券简称：金河生物 公告编号:2025-063 金河生物科技股份有限公司 2025 年半年度业绩预告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司股东 | 盈利：12,742.88 | 万元-14,108.19 万元 | 盈利：9,102.06 | 万元 | | 的净利润 | 比上年同期增长 | 40%-55% | | | | 扣除非经常性损益后 归属于上市公司股东 | 盈利：11,782.73 | 万元–13,148.04 万元 | 盈利：8,494.87 | 万元 | | | 比上年同期增长：38.70%-54.78% | | | | | 的净利润 | | | | | | 基本每股收益 | 盈利：0.1651 | 元/股-0.1828 元/股 | 盈利：0.1166 | 元/股 | 二、与会计师事务所沟通情况 公司本次业绩预告未经注册会计师审计。 三、业绩变动原因说明 本报告期，公司兽 ...

Group 1: Project and Investment Updates - The company has not arranged for the construction of the erythritol project and has no related information to provide at this time [1] - The company has completed fundraising but has no specific plans for the erythritol project, nor a timeline for construction [1] - The company is focusing on existing projects and has no further restructuring plans [2] Group 2: Market and Trade Impact - The trade war has not affected the company's export products, and export volumes remain stable [1] - The company has implemented price increases in the U.S. market to cover tariff costs [1] - The company maintains a stable market share globally, despite fluctuations in international trade [1] Group 3: Product Performance and Sales - The company's chemical drug product, Jinmeisu, has maintained a high reputation and stable supply-demand relationship in the market [2] - The main vaccine product, Blue Ear Inactivated Vaccine, continues to hold the number one market share [2] - The company’s new production capacity for chemical drugs is currently at 100% utilization [2] Group 4: Future Development Strategies - The company aims to enhance product quality, innovation capabilities, and market share to ensure steady profit growth [2] - The company is actively pursuing strategic development goals and aims to achieve a market value of 20 billion [3] - The company is exploring new avenues in the animal health sector while focusing on existing product development [2] Group 5: Financial and Operational Insights - The company’s logistics costs for the first half of 2025 are still being compiled, with details to be disclosed in the upcoming half-year report [5] - The company has invested 158 million in a wastewater treatment project to enhance its capabilities and profitability [4] - The company is closely monitoring the impact of corn price fluctuations on product costs and adjusting procurement strategies accordingly [4]

Market Overview - The Shanghai Composite Index fell by 0.13% on July 9, with 17 out of the 28 sectors rising, led by Media and Agriculture, Forestry, Animal Husbandry, and Fishery, which increased by 1.35% and 0.65% respectively [2] - The sectors with the largest declines were Non-ferrous Metals and Basic Chemicals, which dropped by 2.26% and 0.85% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.536 billion yuan, with only three sectors experiencing net inflows: Media (1.055 billion yuan), Retail (864 million yuan), and Construction Decoration (40.34 million yuan) [2] - The Electronic sector saw the largest net outflow, amounting to 7.789 billion yuan, followed by Non-ferrous Metals with 5.412 billion yuan [2] Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The Agriculture, Forestry, Animal Husbandry, and Fishery sector rose by 0.65% despite a net capital outflow of 437 million yuan [3] - Out of 103 stocks in this sector, 40 stocks increased, with one hitting the daily limit, while 55 stocks declined [3] - The top three stocks with net inflows were Xinwufeng (31.4665 million yuan), Haida Group (28.3706 million yuan), and Juxing Agriculture (21.9941 million yuan) [3][4] Top Gainers and Losers in Agriculture, Forestry, Animal Husbandry, and Fishery - **Top Gainers**: - Xinwufeng: +0.65%, 4.20% turnover, 31.4665 million yuan inflow [4] - Juxing Agriculture: +0.76%, 4.49% turnover, 21.9941 million yuan inflow [4] - **Top Losers**: - Muyuan Foods: -3.27%, 1.81% turnover, 71.5922 million yuan outflow [5] - Guolian Aquatic Products: -1.76%, 8.74% turnover, 45.2607 million yuan outflow [5]

本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002688 证券简称：金河生物 公告编号:2025-062 金河生物科技股份有限公司 关于参加内蒙古辖区上市公司2025年投资者 网上集体接待日活动的公告 2025年7月9日 1 为进一步加强与投资者的互动交流，金河生物科技股份有限公司（以下简 称"公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络 有限公司联合举办的"2025年内蒙古辖区上市公司投资者集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演APP参 与本次互动交流，活动时间为2025年7月11日(周五)16:00-18:00。届时公司高 管将在线就公司2024年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎 广大投资者踊跃参与！ 特此公告。 金河生物科技股份有限公司 董 事 会 ...

Core Viewpoint - The supervisory board of Jinhe Biotechnology Co., Ltd. has reviewed and approved the conditions for the release of restricted stock under the 2023 Restricted Stock Incentive Plan, confirming compliance with relevant laws and regulations [1][3]. Summary by Sections Section 1: Review of Incentive Objects - The company meets the conditions for implementing the stock incentive plan as per the Management Measures and relevant regulations, confirming the eligibility of the incentive objects for the second release period and the first reserved grant period [1][2]. - The incentive objects for the current plan do not fall under any disqualifying conditions as outlined in the Management Measures [2]. Section 2: Approval of Release Conditions - The supervisory board has verified that the 70 initial incentive objects and 11 reserved incentive objects meet the conditions for the release of restricted stocks, with a total of 4,326,000 shares for the initial grant and 500,000 shares for the reserved grant approved for release [3]. Section 3: Repurchase and Cancellation of Restricted Stocks - The supervisory board has determined that 43 incentive objects did not fully meet performance targets, leading to the repurchase and cancellation of their unvested restricted stocks, totaling 2,100,000 shares [3][5]. - The repurchase price adjustment and the process for cancellation have been confirmed to comply with relevant regulations, ensuring no harm to the company or shareholders [4][5].

Summary of Key Points Core Viewpoint - The company, Jinhe Biological Technology Co., Ltd., plans to provide a guarantee of up to 100 million yuan for its wholly-owned subsidiary, Inner Mongolia Jinhe Environmental Technology Co., Ltd., to support its financing needs, which exceeds 50% of the company's latest audited net assets [1][2]. Group 1: Guarantee Overview - The board of directors approved the guarantee proposal with a unanimous vote of 9 in favor [1]. - The maximum guarantee amount is set at 10 million yuan, which represents 4.45% of the company's audited net assets for 2024 [1][4]. - The guarantee will be a joint liability guarantee, with the actual amount and duration to be determined in the final guarantee contract [1]. Group 2: Approval Process - The guarantee must be submitted to the shareholders' meeting for special resolution approval and does not involve related transactions or require approval from relevant authorities [2]. - The effective period of the guarantee is 12 months from the date of the shareholders' meeting resolution [2]. Group 3: Financial Situation of the Guaranteed Party - Inner Mongolia Jinhe Environmental Technology Co., Ltd. is a wholly-owned subsidiary with a registered capital of 50 million yuan and an asset-liability ratio of 32.77% [3]. - The subsidiary's recent financial data shows a revenue of approximately 170.12 million yuan for 2024 and a net profit of about 33.14 million yuan [3]. Group 4: Board's Opinion - The board believes that providing this guarantee will meet the subsidiary's operational funding needs and support its healthy and sustainable development [3]. - The company has the ability to control operational and financial risks during the guarantee period, and this action aligns with the company's long-term interests [3]. Group 5: Cumulative Guarantee Situation - As of the announcement date, the total external guarantee balance of the company and its subsidiaries is approximately 513.73 million yuan, which is 22.87% of the company's audited net assets for 2024 [4]. - The new guarantee of 10 million yuan will increase this percentage to 4.45% [4].

关于增加公司 2025 年日常关联交易预计额度的公告 证券代码：002688 证券简称：金河生物 公告编号：2025-060 金河生物科技股份有限公司 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第六届董事会第二十五次会议、第六届监事会第二十次会议及 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过了《关于公司 2025 年度日常关联交易预计 额度的议案》。公司及子公司 2025 年预计发生接受关联人内蒙古金河建筑安装 有限责任公司（以下简称"金河建安"）提供劳务的基本建设项目及基建维修的 关联交易总额为不超过 5,720 万元。子公司及二级子公司 2025 年预计发生接受 关联人北京中业园净化空调工程有限公司（以下简称"北京中业园"）提供劳务 的日常关联交易总额为不超过 517.50 万元。具体内容详见公司于 2025 年 4 月 会第二十五次会议决议公告》《第六届监事会第二十次会议决议公告》和 2025 年 5 月 24 日披露的《2024 年度股东大会决议的公告》。 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误 ...

Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shanghai) Law Firm confirms the completion of the second unlock period for the initial grant of restricted stock and the first unlock period for reserved grants under the 2023 Restricted Stock Incentive Plan of Jinhe Biotechnology Co., Ltd, along with the repurchase and cancellation of certain restricted stocks and adjustments to the repurchase price [1][2][22]. Group 1: Unlock Conditions and Achievements - The second unlock period for the initial grant of restricted stocks is set to be 24 months after the registration completion date, which was completed on July 7, 2023 [13][14]. - The first unlock period for reserved grants is 12 months after the registration completion date, which was completed on December 28, 2023 [14]. - The company has met the performance assessment requirements for the unlock conditions, with a net profit growth rate of 88.29% in 2024, exceeding the required 78% [17][18]. Group 2: Repurchase and Price Adjustment - The company plans to repurchase and cancel a total of 2,100,000 shares of restricted stock due to the departure of certain incentive targets and performance failures [21][22]. - The adjusted repurchase price for the restricted stocks is set at 2.29 yuan per share, following a cash dividend distribution of 1.00 yuan per 10 shares [19][22]. - The repurchase will be funded by the company's own funds, and the repurchase reasons, quantity, price, and funding sources comply with relevant regulations [22].